Almoosa, 226 patient favipiravir late treatment study: 42% higher mortality [p=0.1], 90% higher ICU admission [p=0.02], and 11% slower recovery [p=0.17] https://c19p.org/almoosa
copied to clipboard
Favipiravir versus Standard of Care in Patients with Severe COVID-19 Infections: A Retrospective Comparative Study
et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.08.022
Retrospective 226 COVID-19 pneumonia patients, 110 treated with favipiravir, showing higher mortality (p=0.1) and ICU admission (p=0.02) with treatment in multivariate analysis.
|
risk of death, 42.3% higher, RR 1.42, p = 0.10, treatment 33 of 110 (30.0%), control 24 of 116 (20.7%), adjusted per study, odds ratio converted to relative risk, overall mortality, multivariate binary logistic regression.
|
|
risk of ICU admission, 90.0% higher, OR 1.90, p = 0.02, treatment 110, control 116, adjusted per study, multivariate binary logistic regression, RR approximated with OR.
|
|
recovery time, 10.9% higher, relative time 1.11, p = 0.17, treatment 110, control 116.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Almoosa et al., 8/24/2021, retrospective, Saudi Arabia, Middle East, peer-reviewed, 14 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.